SEC Filing Summary: Spherix Incorporated (Form 10-Q)
Business Context and Reporting Period
This filing covers the quarterly period ended June 30, 2003, for Spherix Incorporated (formerly Biospherics Incorporated). The company operates two primary business segments: InfoSpherix (government and commercial reservation systems) and BioSpherix (biotechnology, specifically sweeteners like tagatose and Naturlose). The financial statements are unaudited.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2003 | Six Months Ended June 30, 2003 |
|---|---|---|
| Revenue | $4,802,124 | $9,222,906 |
| Net Loss | $(453,075) | $(1,139,463) |
| Loss Per Share (Diluted) | $(0.04) | $(0.10) |
| Cash and Cash Equivalents | $4,747,790 (as of June 30, 2003) | |
| Working Capital | $7,890,140 (Current Assets $10.9M - Current Liabilities $3.0M) | |
| Debt (Bank Line of Credit) | $1,108,816 outstanding; $891,184 available | |
| Operating Cash Flow | $(1,282,116) used in operating activities (6 months) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 14% ($576k) for the quarter and 26% ($1.93M) for the six months compared to 2002, driven primarily by new contracts in the InfoSpherix segment.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose 38% ($419k) for the quarter, largely due to approximately $525,000 in legal fees related to arbitration with Arla Foods and National Park Service (NPS) procurement disputes.
- Segment Performance:
- InfoSpherix: Generated an operating income of $180,000 for the quarter, a significant improvement from $4,000 in the prior year.
- BioSpherix: Reported an operating loss of $(638,000) for the quarter, worsening from $(328,000) in 2002, due to decreased FlyCracker sales and increased R&D/legal costs.
- Liquidity: Cash and cash equivalents decreased by approximately $3.9 million over the six-month period, primarily due to operating outflows and the purchase of restricted investments ($2.49M) to collateralize the bank line of credit.
Guidance, Outlook, and Risks
- Legal Proceedings (Arla Foods): The company is in arbitration with licensee Arla Foods regarding the commercialization of tagatose. The company has incurred ~$1.0 million in legal expenses to date and expects significant additional costs. A decision is anticipated in Q1 2004.
- Government Contracts (NPS): The National Park Service cancelled the procurement for the National Park Reservation System. While the contract was extended through September 30, 2003, a competitive procurement for the combined NPS and National Forest Service system is expected in Spring 2004. The company has filed protests regarding the bundling of contracts.
- BioSpherix Outlook: Arla Foods made tagatose commercially available in Q2 2003; royalties are expected to begin in August 2003. The company is also pursuing commercial opportunities for Naturlose (tagatose for cosmetics) and a new patent for prolonging fragrance life.
- Capital Needs: Management anticipates sufficient cash flow from operations to cover continuing capital needs for 2003, including system upgrades.
Investor Verification Checklist
- Verify the status and potential financial impact of the arbitration with Arla Foods, including the likelihood of royalty payments commencing in August 2003.
- Confirm the outcome of the National Park Service (NPS) contract protests and the terms of the upcoming Spring 2004 competitive procurement.
- Monitor the company's cash burn rate given the $1.3M operating cash outflow in the first half of 2003 and the $2.0M restricted investment.
- Assess the progress of Naturlose commercialization and the potential revenue from the new fragrance patent.
- Review the bank line of credit covenants to ensure continued compliance as the company manages its debt and working capital.